Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume 7, Issue 4, Pages 443-450
Publisher
Informa UK Limited
Online
2014-04-19
DOI
10.1586/17512433.2014.909723
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): A first-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent dosed once daily on days 1, 2, 3, and 4 of a 21-day cycle.
- (2017) P. P. Peethambaram et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ovarian cancer: genomic analysis
- (2013) W. Wei et al. ANNALS OF ONCOLOGY
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid–poly(ethylene glycol)–chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy
- (2013) Tony Shing Chau Li et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
- (2013) Deborah K. Armstrong et al. GYNECOLOGIC ONCOLOGY
- Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
- (2013) Thomas J. Herzog et al. GYNECOLOGIC ONCOLOGY
- PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
- (2013) R. Wendel Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy
- (2013) Josefine Reber et al. MOLECULAR CANCER THERAPEUTICS
- Precursors and pathogenesis of ovarian carcinoma
- (2013) D. Lim et al. PATHOLOGY
- Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro
- (2012) B. A. Kamen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
- (2012) Patricia M. LoRusso et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
- (2012) Nicoletta Colombo et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
- (2012) Lana E Kandalaft et al. Journal of Translational Medicine
- Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome
- (2012) Michelle K. Y. Siu et al. PLoS One
- Folate-decorated nanogels for targeted therapy of ovarian cancer
- (2011) Natalia V. Nukolova et al. BIOMATERIALS
- Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
- (2011) R. Wendel Naumann et al. DRUGS
- In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin)
- (2011) Pradeep K. Naik et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
- (2011) Yu-Li Chen et al. Molecular Oncology
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?
- (2010) Edward J. Tanner et al. GYNECOLOGIC ONCOLOGY
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
- (2010) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
- (2010) Gordon JS Rustin et al. LANCET
- Making the best of PARP inhibitors in ovarian cancer
- (2010) Susana Banerjee et al. Nature Reviews Clinical Oncology
- Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
- (2009) David S. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started